NCT01994382 - Phase 1/2a Dose Escalation Study in Participants With CLL, SLL, or NHL | Biotech Hunter

Enrollment

260

Participants

Timeline

Start Date

August 30, 2013

Primary Completion Date

December 15, 2020

Study Completion Date

December 15, 2020

Conditions

Follicular Lymphoma (FL/Indolent NHL)Aggressive NHL (a NHL)Chronic Lymphocytic Leukemia (CLL) / Small Lymphocytic Lymphoma (SLL)T-cell Lymphoma (PTCL and CTCL)B-cell Non Hodgkin Lymphoma (NHL)

Interventions

DRUG

Cerdulatinib

Oral capsule

BIOLOGICAL

Rituximab

IV infusion

Trial Locations (23)

10021

New York

19104

Philadelphia

20007

Washington D.C.

21229

Baltimore

23226

Richmond

29412

Charleston

30046

Lawrenceville

32608

Gainesville

34232

Sarasota

35805

Huntsville

39402

Hattiesburg

40207

Louisville

48109

Ann Arbor

53226

Milwaukee

60637

Chicago

76012

Arlington

79410

Lubbock

85234

Gilbert

90095

Los Angeles

94304

Palo Alto

98109

Seattle

07601

Hackensack

07960

Morristown